Search
Close this search box.

Clinics treatment systemic hashimoto's thyroiditis erythematosus systemicus Zaragoza

We are a European reference centre for the diagnosis and treatment of autoimmune diseases.

What is Hashimoto's thyroiditis disease?

Hashimoto's thyroiditis is a autoimmune disease which affects the thyroid gland so that it loses its ability to produce sufficient thyroid hormones. Hashimoto's disease can lead to hypothyroidism.

Hypothyroidism explains states of depression and other psychiatric illnesses as thyroid hormone is essential for brain function.

Causes of Hashimoto's thyroiditis

Although it is not possible to determine a cause of chronic thyroiditis, there are different risk factors:

  • This disease affects more women.
  • The immune status that occurs in pregnancy and after childbirth can lead to thyroid problems that disappear within 12 to 18 months. However, women who have had postpartum thyroiditis are more likely to develop chronic thyroiditis.
  • Genetic factors or family history
  • Previous endocrine disorders caused by the immune system
  • Polyglandular autoimmune syndrome, which may result in Hashimoto's disease.

Symptoms of Hashimoto's thyroiditis

The inflammation caused by Hasimoto's thyroiditis is pathological and leads to progressive destruction of the thyroid. Tissue loss occurs, which is manifested externally as a tendency to tiredness, slowness of thought and movement. Another Typical symptoms of thyroid deficiency are weight gain or heavier than normal menstrual periods in women.

On the other hand, it is very common to suffer from the disease without symptoms for years and to notice the first symptom of an enlarged thyroid when the disease has progressed. Goitre, however, is not painful.

Treatment of Hashimoto's Thyroiditis

As we regulate the immune system, the level of antibodies decreases. With a personalised treatment of Biological Medicine we will be able to stop the autoimmune process and we will be supported by the regenerative medicine to recover the tissue.

Subscribe to our newsletter